MET4 Antibody

What is METTL4 and why is it significant in epigenetic research?

METTL4 (Methyltransferase-like protein 4) is an N(6)-adenine-specific methyltransferase that plays critical roles in both RNA and DNA methylation. Significantly, METTL4 catalyzes the formation of N6,2'-O-dimethyladenosine (m6Am) on internal positions of U2 small nuclear RNA (snRNA), which impacts RNA splicing regulation . Additionally, METTL4 can function as a DNA methyltransferase by mediating N(6)-methyladenosine (m6A) modifications, although this role remains somewhat controversial in mammals . METTL4 also regulates mitochondrial transcript levels and mitochondrial DNA copy numbers through mtDNA N(6)-methylation, where m6A on mtDNA reduces transcription by repressing TFAM DNA-binding and bending . These diverse functions make METTL4 a significant target for epigenetic research.

How do METTL4 antibodies differ from MT4 antibodies?

Despite the similar nomenclature, METTL4 and MT4 antibodies target entirely different proteins. METTL4 antibodies recognize Methyltransferase-like protein 4, which functions in RNA and DNA methylation as described above . In contrast, MT4 antibodies target Metallothionein 4, a small protein (62 amino acids, 6.5 kDa) belonging to the Metallothionein protein superfamily . These proteins have distinct molecular weights (METTL4 is significantly larger) and completely different cellular functions. When ordering antibodies, researchers must carefully confirm whether they need antibodies against METTL4 or MT4 to avoid experimental confusion .

What applications are METTL4 antibodies typically validated for?

METTL4 antibodies are primarily validated for Western blotting (WB), with recommended dilutions typically ranging from 1:1000 to 1:2000 . Some antibodies may also be validated for immunohistochemistry on paraffin-embedded tissues (IHC-P) . Depending on the specific antibody, they may be suitable for immunocytochemistry (ICC) and immunofluorescence (IF) applications . Researchers should carefully review validation data before selecting an antibody for a specific application, as reactivity can vary significantly between manufacturers and individual antibody lots.

How should researchers select the appropriate METTL4 antibody for their experiments?

When selecting a METTL4 antibody, researchers should consider these key factors:

• Target species compatibility: Verify the antibody's reactivity with your experimental species. For example, many METTL4 antibodies react with human, mouse, and rat samples .

• Application suitability: Confirm the antibody has been validated for your specific application (WB, IHC-P, ICC, etc.) .

• Immunogen information: Review the specific sequence the antibody was raised against. For instance, some antibodies target amino acids 1-190 of human METTL4, while others target amino acids 1-150 .

• Clonality: Determine whether a polyclonal or monoclonal antibody is more suitable for your research. Polyclonal antibodies may offer higher sensitivity but potentially lower specificity than monoclonal antibodies.

• Validation evidence: Examine published validation data and positive control samples (e.g., A-549, 293T, HeLa, MCF7, mouse brain, or rat brain for some METTL4 antibodies) .

What are the recommended storage conditions and handling practices for METTL4 antibodies?

For optimal maintenance of METTL4 antibody activity:

• Store antibodies at -20°C as recommended by manufacturers .

• Avoid repeated freeze-thaw cycles by aliquoting the antibody upon receipt.

• Store in appropriate buffer conditions, typically PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 .

• When working with the antibody, keep it on ice and return to storage promptly.

• Always check the manufacturer's specific recommendations, as storage conditions may vary between products.

• Monitor expiration dates and validate antibody performance periodically, especially with older stock solutions.

What positive controls are recommended for validating METTL4 antibody performance?

For reliable validation of METTL4 antibodies, the following positive controls have been demonstrated to express detectable levels of METTL4:

When validating a new antibody lot or applying METTL4 antibodies to a new experimental system, researchers should include at least one of these positive controls alongside their experimental samples.

How can METTL4 antibodies be utilized to investigate RNA methylation mechanisms?

METTL4 antibodies can be employed in sophisticated experimental approaches to elucidate RNA methylation mechanisms:

• RNA Immunoprecipitation (RIP): Using METTL4 antibodies to precipitate METTL4-bound RNA complexes, researchers can identify specific RNA targets of METTL4-mediated methylation. This approach can be coupled with sequencing (RIP-seq) to obtain transcriptome-wide binding profiles .

• Chromatin Immunoprecipitation (ChIP): While METTL4 primarily functions in RNA methylation, its potential role in DNA methylation can be investigated using ChIP with METTL4 antibodies to identify genomic binding sites .

• Immunofluorescence co-localization: METTL4 antibodies can be used to visualize the subcellular localization of METTL4 in relation to other components of the RNA methylation machinery, providing insights into the spatial organization of these processes .

• Proximity Ligation Assay (PLA): This technique can detect protein-protein interactions between METTL4 and potential binding partners involved in RNA methylation, helping to elucidate the composition of METTL4-containing complexes.

• Methylated RNA Immunoprecipitation (MeRIP): While not directly using METTL4 antibodies, this technique can be combined with METTL4 knockdown/overexpression to identify specific methylation sites regulated by METTL4 .

What experimental approaches can determine if METTL4 acts as both an RNA and DNA methyltransferase?

The dual role of METTL4 as both an RNA and DNA methyltransferase requires careful experimental design:

• In vitro methyltransferase assays: Using purified METTL4 protein and radiolabeled methyl donors (S-adenosylmethionine), researchers can assess METTL4's ability to methylate RNA and DNA substrates in controlled conditions.

• Comparison of methylation profiles: Following METTL4 knockout or overexpression, researchers can compare changes in both RNA methylation (using MeRIP-seq) and DNA methylation (using whole-genome bisulfite sequencing or 6mA-specific detection methods).

• Substrate specificity analysis: By introducing mutations in METTL4's catalytic domain and testing methyltransferase activity on different substrates, researchers can determine if the same catalytic mechanism is responsible for both RNA and DNA methylation.

• Structural biology approaches: X-ray crystallography or cryo-EM of METTL4 bound to different substrates can provide insights into whether the protein can accommodate both RNA and DNA molecules.

• Domain deletion/swapping experiments: By generating METTL4 variants with modified domains, researchers can determine which regions are essential for RNA versus DNA methylation activity .

It's worth noting that while METTL4 has been implicated in DNA 6mA methylation, additional biochemical evidence is still needed to conclusively establish METTL4 as a DNA methyltransferase in mammals .

How can researchers investigate the relationship between METTL4 and mitochondrial function?

To examine METTL4's role in mitochondrial regulation:

• Mitochondrial fractionation: METTL4 antibodies can be used to determine whether METTL4 localizes to mitochondria under various cellular conditions.

• Analysis of mtDNA methylation: Researchers can isolate mitochondrial DNA and assess 6mA levels in the presence or absence of METTL4 using techniques such as 6mA-IP-seq or single-molecule real-time sequencing.

• Mitochondrial transcriptome analysis: RNA-seq of mitochondrial transcripts following METTL4 modulation can reveal how METTL4-mediated methylation impacts mitochondrial gene expression .

• TFAM binding assays: Since METTL4-mediated mtDNA methylation reportedly reduces TFAM binding, electrophoretic mobility shift assays (EMSAs) using methylated versus unmethylated mtDNA can quantify this effect .

• Mitochondrial function assays: Measurements of oxygen consumption rate, ATP production, and mitochondrial membrane potential in cells with altered METTL4 expression can establish connections between METTL4 activity and mitochondrial function.

What are common challenges when using METTL4 antibodies for Western blotting and how can they be addressed?

Researchers frequently encounter these challenges when using METTL4 antibodies in Western blotting:

For optimal Western blotting results with METTL4 antibodies, adhere to the manufacturer's recommended dilution (typically 1:1000-1:2000) and validate with known positive control samples like A-549, 293T, HeLa, or MCF7 cell lysates .

How can researchers validate METTL4 antibody specificity for immunohistochemistry applications?

To ensure METTL4 antibody specificity in immunohistochemistry:

• Peptide competition assay: Pre-incubate the METTL4 antibody with the immunizing peptide before application to tissue sections. Specific staining should be eliminated or significantly reduced.

• METTL4 knockdown/knockout controls: Compare staining between wild-type tissues and those with genetically reduced METTL4 expression.

• Multiple antibody validation: Use different METTL4 antibodies targeting distinct epitopes to confirm consistent staining patterns.

• Tissue panel analysis: Examine staining across multiple tissues with known differential expression of METTL4 to confirm the antibody detects expected expression patterns.

• Positive/negative controls: Include tissues with known METTL4 expression (e.g., brain tissue) as positive controls and tissues where METTL4 expression is expected to be minimal as negative controls .

• Antibody titration: Perform serial dilutions of the antibody to identify optimal concentration that maximizes specific signal while minimizing background.

• Comparison with RNA expression data: Cross-validate IHC results with RNA-seq or qPCR data showing METTL4 expression patterns across tissues.

How might METTL4 antibodies be utilized to investigate connections between RNA methylation and disease?

METTL4 antibodies can facilitate several experimental approaches to explore RNA methylation in disease contexts:

• Tissue microarray analysis: METTL4 antibodies can be applied to disease-specific tissue microarrays to assess whether METTL4 expression correlates with disease progression or outcomes, particularly in cancer and neurological disorders .

• Single-cell analysis: Combining METTL4 immunostaining with single-cell RNA-seq can reveal cell type-specific variations in METTL4 expression within heterogeneous disease tissues.

• Patient-derived xenograft models: METTL4 antibodies can track changes in METTL4 expression and localization during disease progression in these models, potentially identifying therapeutic intervention points.

• Proximity-based proteomics: Techniques like BioID or APEX using METTL4 as bait can identify disease-specific protein interactions that may represent novel therapeutic targets.

• ChIP-seq in disease models: Although the DNA methyltransferase activity of METTL4 remains debated, ChIP-seq with METTL4 antibodies in disease models could reveal altered chromatin binding patterns associated with pathological states .

Disease contexts of particular interest include cancers where epigenetic dysregulation is prominent and neurological disorders where RNA processing plays critical roles.

What future technical developments might enhance the utility of METTL4 antibodies in research?

Several technical innovations could significantly advance METTL4 antibody applications:

• Phospho-specific METTL4 antibodies: Development of antibodies recognizing specific post-translational modifications of METTL4 would enable researchers to track regulatory changes in METTL4 activity.

• Nanobodies and intrabodies: Smaller antibody formats that can penetrate live cells would allow real-time tracking of METTL4 localization and activity.

• CRISPR-directed antibody tagging: By inserting epitope tags into endogenous METTL4 loci, researchers could overcome specificity limitations of conventional antibodies.

• Split-antibody complementation systems: These would enable detection of METTL4 only when it interacts with specific binding partners or adopts certain conformations.

• Transcriptome-wide mapping tools: Development of METTL4 antibodies specifically optimized for techniques like CLIP-seq would enhance our understanding of METTL4's RNA targets .

• Quantitative super-resolution microscopy: Combining METTL4 antibodies with advanced imaging techniques could reveal the spatial organization of METTL4-containing complexes at unprecedented resolution.

Future research would benefit significantly from transcriptome-wide mapping of internal m6Am modifications and CLIP-seq analysis of METTL4, which would provide comprehensive insights into METTL4's regulatory networks .